Celebrex:
Let the Trials Begin It’s good for arthritis, it’s
under study for Alzheimer’s, and last month, national trials
got under way exploring the anti-inflammation drug Celebrex as a
possible ALS therapy. At the Center for ALS Research and 24 other
sites, volunteers in early stages of the disease have begun receiving
daily high doses.
Sponging
Up Glutamate? Good Idea A new study by Center scientist Margaret Sutherland,
Ph.D., not only shores up a long-held idea on a major source of
cell damage in ALS but also shows something can be done to fix it,
at least in mice.
An
Eye on the Shore Centerwide stem cell research keeps hopes
afloat in its early stages. But so far, every study answers questions
that lead to more.
The New
Rat Model: Bigger Is Better A new rat model of the disease that’s
far easier to work with and more versatile than earlier mouse models.
Vantage
point
One of the most satisfying things about directing the Center has
been watching the shift in our thinking about the biology of ALS.
On
Center: Fund-Raisers’ Bounty Keeps Center on Track
It’s a rare foundation that doesn’t have to depend on
fund raising. With the Center for ALS Research, dedicated as it
is to a high volume and a rapid turnout of lab results, benefits
and such events are crucial. But even for this stepped-up place,
the pace has been fast.
Insider’s
View
Daniel Drachman, M.D., is a longtime Hopkins neurologist / researcher
who specializes in neuromuscular diseases. In this column he answers
questions.
From
the Clinic
Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS
clinic. She also oversees its clinical trials. In this column she
answers typical patients’ questions.
A
Friend Indeed: Orioles Hit Home Runs for ALS
With the Orioles and ALS research, the connection was serendipity.
Everything just fell into place the summer of 1995, when Oriole
great Cal Ripken was on the verge of breaking Lou Gehrig’s
consecutive-games-
played record.